Gene Therapy In Oncology Innovation To Commercialization Competitive Landscape
DelveInsight report “Gene Therapies in Oncology - Innovation to Commercialization: Competitive Landscape, Technological Advancements, Market Opportunities & Future Directions, 2018” includes Comprehensive Insights on Cancer Gene Therapy by Market Trends, Competitive Landscape, Clinical Trials, Regulatory Considerations, Potential Geographies Licensing Opportunities, Top Cancer Indications, Vectors (Viral, Non-Viral, Engineered nucleases) and Advancements in Technology. It provides information across the entire gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, and funding and licensing opportunities. Using the propriety DelveInsight Competitive Matrix models, the report also provides the first in class market analytics providing predictive analysis of early market winners of the clinical therapies in a demographic presentation view.
It has covered ~50 gene therapies covering 34 Pharmaceutical companies. Studies have been performed for approximately 60+ specific indications under Oncology. The companies are utilizing 26 different technology platforms which have inherent uniqueness and robustness. The Report also gives insights about the vectors usage in Gene therapy which are approximately 82% for viral vectors, 11% for the Non-Viral vectors and 7% for the Bacterial vectors.
The power of cell and gene therapies targeted for the life-threatening and high unmet need diseases have been the driving force behind academics, small biotech firms; and now large pharmaceutical companies which are also actively investing time and resources in this rapidly evolving area. The concept of human gene therapies had emerged in 1989, with the first approved human gene therapy trial of Rosenberg et al., which investigated the use of human tumor-infiltrating lymphocytes (TIL) modified genetically by introducing the gene coding for resistance to neomycin into TIL for patients with advanced melanoma. The discipline as a whole received a moderate push during the 1990's until the elucidation of the human genome in 2003.There has been no looking back since then, and thereafter leading up to a stage where gene therapy is touted as the next big thing in the healthcare space; and is set to break the existing barriers and create new horizons.
The report covers a descriptive account of Gene Therapy in oncology, inclusive of its historical timeline & its evolution over the years, types, and vectors along with the corresponding gene-transfer methods as well as delivery techniques, apart from advancements in technologies.
Coverage of cancer gene therapy candidates under development worldwide, showcasing their relative positioning in global Oncology therapeutic space.
Breakdown of Pipeline candidates across different phases, emerging trends and comparative analysis of the products with detailed clinical profiles, Targets, Designations, Technologies, Combination drugs along with product development activities.
In-depth analysis of developmental gene therapy molecules based on cancer indication, types of vector, clinical staging and by geography.
Comprehensive insight is provided into licensing & collaboration opportunities and funding details for emerging gene therapies.
Matrix analysis, based on clinical and commercial scoring of promising therapies under late-stage development, to predict their regulatory success and subsequent market penetration.
Mapping of Clinical trials based upon the trial design, targeted cancer indications and geography.
A detailed review of the regulatory guidelines/framework for the approval of gene therapy across the 7MM [US, EU5 countries and Japan].
Additionally, an all-inclusive account of the currently marketed gene therapies in Oncology and their commercial impact in the market covered.
The report provides an edge while formulating business strategies by enabling comprehensive understanding of the historical trends, present challenges and future developmental. opportunities for Cancer Gene Therapy; which will help in prudently positioning in the market against competitors.